Compounded Semaglutide Providers in 2026 — Ranked & Reviewed
Compounded semaglutide is a low-cost alternative to brand-name Wegovy and Ozempic, made by 503A and 503B pharmacies under physician supervision. We ranked the most reputable telehealth clinics offering compounded semaglutide in 2026 by price, pharmacy verification, clinical care, and shipping. Every provider on this list ships nationwide.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support. Compounded GLP-1s from licensed 503A and 503B pharmacies are legal under federal compounding law[2], with additional tolerances historically allowed while semaglutide and tirzepatide were on the FDA Drug Shortage List[3].
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Enhance MD
Verified partnerBest for: lab-monitored compounded GLP-1 with mandatory video visit
Enhance MD pairs compounded semaglutide and tirzepatide with mandatory baseline metabolic labs at Quest Diagnostics and a synchronous video visit with a board-certified clinician — a more rigorous onboarding than the async-only compounded GLP-1 model most telehealth providers use. Three tiers (Core semaglutide, Advanced tirzepatide, Elite combined) plus aggressive intro pricing ($49 first month on Core).
Score Breakdown
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Low first-month intro pricing: $49 Core, $99 Advanced, $189 Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro pricing resets to full tier rate after 30 days — the $49/$99/$189 figures aren't ongoing cost
Embody
Verified partnerBest for: lowest first-month entry pricing on compounded GLP-1s
Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
Score Breakdown
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
TrimRx
Verified partnerBest for: best overall value
TrimRx is a telehealth weight-loss program offering compounded semaglutide prescribed by licensed US medical providers after an online medical-history review, with medication shipped monthly and free shipping. It leans on price stability and dose continuity — "switch and keep your current dose, no price hikes" — and needs no insurance (cash-pay, tiered monthly pricing plus multi-month bundles). Compounded GLP-1s are not FDA-approved. The compounding pharmacy and state list are not published, specifics are gated behind the intake quiz, and no LegitScript certification is shown.
Score Breakdown
Pros
- ✓Compounded semaglutide prescribed by licensed US medical providers after an online medical-history review
- ✓Free shipping with medication delivered to your door monthly — can start as soon as the next day
- ✓Price-stability positioning: "switch and keep your current dose," with no advertised mid-program price hikes
- ✓Tiered monthly pricing from ~$179/mo plus discounted multi-month bundles; no insurance required (cash-pay)
- ✓24/7 patient portal for support; publishes HIPAA, privacy, SMS, and terms policies
Cons
- ✗Async, questionnaire-based intake — no mandatory video visit with a clinician before prescribing
- ✗Compounded semaglutide is not FDA-approved (the site discloses this) — it is not brand Wegovy or Ozempic
- ✗Only compounded semaglutide injections are advertised — tirzepatide and oral options are not publicly listed
- ✗Compounding pharmacy partner is not named, and the state-availability list is not published
- ✗Pricing tiers and program details are gated behind the intake quiz; no LegitScript certification displayed
Telos Rx
Verified partnerBest for: Needle-free and microdosed compounded GLP-1 options with lab-monitored care
Telos Rx is a compounded telehealth platform (Superior Health Solutions LLC) offering GLP-1 weight loss alongside longevity, recovery, and sexual-health peptides. Its GLP-1 line includes compounded semaglutide and tirzepatide injections plus needle-free sublingual and microdosed tirzepatide, with provider dose adjustments, lab monitoring, free discreet shipping, FSA/HSA, and cancel-anytime. Headline prices are first-month intro rates (from $49); ongoing cost is higher. Compounded meds are not FDA-approved; pharmacy and states unpublished; no LegitScript shown.
Score Breakdown
Pros
- ✓Multiple GLP-1 modalities: compounded semaglutide and tirzepatide injections plus needle-free sublingual and microdosed tirzepatide
- ✓Provider-led dose adjustments and lab monitoring as your protocol changes
- ✓Free discreet, temperature-controlled shipping (no Telos branding on the outside)
- ✓FSA/HSA eligible and cancel anytime in one click
- ✓Trustpilot rating of 4.9; full compliance suite published (Privacy, Terms, HIPAA, Shipping & returns)
- ✓Integrated care team spanning weight loss, longevity, recovery, and sexual health (peptide-led)
Cons
- ✗Headline pricing is 'first month low as' intro pricing (semaglutide $49, tirzepatide $99) — ongoing monthly cost is higher and shown during intake
- ✗Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- ✗Compounding pharmacy partner is not named
- ✗State-availability list is not published
- ✗No LegitScript certification displayed
Strut Health
Verified partnerBest for: oral-lozenge compounded GLP-1 access
Strut Health offers LegitScript + ACHC-accredited compounded semaglutide and tirzepatide in both injectable and oral lozenge formats, shipping to 49 states. Board-certified US physicians handle prescribing with free unlimited follow-up messaging, but eligibility is gated behind a 'medical necessity' clinician determination that isn't publicly defined.
Score Breakdown
Pros
- ✓Both LegitScript and ACHC accredited — pharmacy oversight most compounded GLP-1 providers don't carry
- ✓Oral lozenge option for semaglutide ($99/mo) and tirzepatide ($199/mo) — an injection-free alternative
- ✓Auto-refill pricing saves 13–21% vs one-off orders
- ✓Free unlimited follow-up messaging with board-certified US physicians
- ✓Ships to 49 states (only Arkansas excluded)
Cons
- ✗Requires a "medical necessity" review, but the criteria aren't published — you can't self-screen before paying for a consult
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Pharmacy partners aren't named — you can't verify the compounding source
- ✗No insurance accepted — cash pay only
- ✗Phone consultation requirement varies by state
Related Rankings
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Wegovy · Drugs and brands
- Ozempic · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Drug Shortage List · Insurance and regulatory
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.